, a global CRO focused on early-stage toxicology and development, has acquired Midwest BioResearch
(MBR), a Chicago-based CRO focused on preclinical drug disposition and toxicology services.
MBR’s background is in immunoanalytical and bioassay techniques, small molecule bioanalysis, and genetic toxicology. WIL believes that this will complement its own offerings, which include chronic, neuro-, inhalation, and intravenous toxicology, developmental and reproductive toxicology, safety pharmacology, bioanalytical chemistry, and metabolism.
“Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities,” says Christopher P. Chengelis, Ph.D., vp and CSO at WIL Research.
With the addition of MBR, WIL Research Holding now comprises five companies with approximately 1,100 employees in the U.S., Europe, and Japan.
To comment on this story, go to BLOGbiotech.